查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1982395

全球人類胰島素市場規模、佔有率、趨勢和成長分析報告（2026-2034）

Global Human Insulin Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計人類胰島素市場將從 2025 年的 593.9 億美元成長到 2034 年的 1,035.3 億美元，2026 年至 2034 年的複合年成長率為 6.37%。

隨著全球糖尿病盛行率的上升，全球人類胰島素市場也顯著成長。人類胰島素廣泛用於調節糖尿病患者的血糖值，特別適用於第1型糖尿病和晚期第2型糖尿病患者。隨著全球糖尿病患者人數的持續成長，對胰島素治療的需求也急劇增加。

多種因素正在推動人類胰島素市場的擴張。糖尿病管理意識的提高、醫療服務可近性的改善以及製藥生產技術的進步，都促進了胰島素供應量的增加。各國政府和醫療機構也正在實施相關項目，以改善糖尿病治療並確保患者獲得必要的藥物。此外，胰島素給藥系統的技術進步也提高了治療的便利性。

隨著醫療衛生系統日益重視改善糖尿病的治療和管理，人類胰島素市場仍前景廣闊。研發工作致力於開發更有效的胰島素製劑，並改善長期治療效果。新興國家醫療衛生基礎設施的持續改善將進一步推動市場成長。鑑於糖尿病仍然是全球面臨的一項重大健康挑戰，預計對人類胰島素治療的需求將保持強勁。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球人類胰島素市場：依產品類型分類

  • 市場分析、洞察與預測
  • 藥品（人類胰島素類似物及生物相似藥（速效、長效、預混合料）、人類胰島素生技藥品（速效、中效、預混合料））
  • 注射裝置（注射筆（可重複使用注射筆、一次性注射筆）、注射針（標準注射針、安全注射針））
  • 注射器
  • 其他

第5章：全球人胰島素市場：依通路分類

  • 市場分析、洞察與預測
  • 零售藥房
  • 醫院藥房
  • 線上零售商店
  • 其他

第6章 全球人類胰島素市場：依疾病類型分類

  • 市場分析、洞察與預測
  • 1型糖尿病
  • 2型糖尿病

第7章 全球人類胰島素市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • B. Braun Melsungen AG
    • Becton Dickinson And Company（BD）
    • Biocon Limited
    • Eli Lilly And Company
    • Gulf Pharmaceutical Industries PSC（Julphar）
    • Novo Nordisk A/S
    • Pfizer Inc
    • Sanofi
    • SEDICO Pharmaceutical Co
    • Wockhardt Limited
    • Ypsomed AG
簡介目錄
Product Code: VMR11211610

The Human Insulin Market size is expected to reach USD 103.53 Billion in 2034 from USD 59.39 Billion (2025) growing at a CAGR of 6.37% during 2026-2034.

The global human insulin market has grown significantly due to the increasing prevalence of diabetes worldwide. Human insulin is widely used to regulate blood sugar levels in individuals with diabetes, particularly those with type 1 diabetes and advanced type 2 diabetes. As the number of diabetes cases continues to rise globally, the demand for insulin therapies has increased substantially.

Several factors are driving the expansion of the human insulin market. Growing awareness of diabetes management, improved healthcare access, and advancements in pharmaceutical manufacturing have contributed to higher insulin availability. Governments and healthcare organizations are also implementing programs to improve diabetes treatment and ensure patient access to essential medications. Additionally, technological improvements in insulin delivery systems are enhancing treatment convenience.

The future of the human insulin market remains promising as healthcare systems focus on better diabetes care and management. Research efforts are aimed at developing more effective insulin formulations and improving long-term treatment outcomes. Expanding healthcare infrastructure in emerging economies will further support market growth. As diabetes continues to be a major global health challenge, demand for human insulin therapies is expected to remain strong.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

  • Drugs (Human Insulin Analogs and Biosimilars (Rapid Acting, Long Acting, Premixed), Human Insulin Biologics (Short Acting, Intermediate Acting, Premixed))
  • Delivery Devices(Pens (Reusable Pens, Disposable Pens), Pen Needles (Standard Pen Needles, Safety Pen Needles))
  • Syringes
  • Others

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Retail Stores
  • Others

By Disease Type

  • Type I Diabetes
  • Type II Diabetes

COMPANIES PROFILED

  • B Braun Melsungen AG, Becton Dickinson and Company BD, Biocon Limited, Eli Lilly and Company, Gulf Pharmaceutical Industries PSC Julphar, Novo Nordisk AS, Pfizer Inc, Sanofi, SEDICO Pharmaceutical Co, Wockhardt Limited, Ypsomed AG
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL HUMAN INSULIN MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Product Type
  • 4.2. Drugs (Human Insulin Analogs and Biosimilars (Rapid Acting, Long Acting, Premixed), Human Insulin Biologics (Short Acting, Intermediate Acting, Premixed)) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Delivery Devices(Pens (Reusable Pens, Disposable Pens), Pen Needles (Standard Pen Needles, Safety Pen Needles)) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Syringes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HUMAN INSULIN MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Distribution Channel
  • 5.2. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Online Retail Stores Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HUMAN INSULIN MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Disease Type
  • 6.2. Type I Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Type II Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HUMAN INSULIN MARKET: BY REGION 2022-2034(USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Product Type
    • 7.2.2 By Distribution Channel
    • 7.2.3 By Disease Type
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Product Type
    • 7.3.2 By Distribution Channel
    • 7.3.3 By Disease Type
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Product Type
    • 7.4.2 By Distribution Channel
    • 7.4.3 By Disease Type
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Product Type
    • 7.5.2 By Distribution Channel
    • 7.5.3 By Disease Type
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Product Type
    • 7.6.2 By Distribution Channel
    • 7.6.3 By Disease Type
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL HUMAN INSULIN INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 B. Braun Melsungen AG
    • 9.2.2 Becton Dickinson And Company (BD)
    • 9.2.3 Biocon Limited
    • 9.2.4 Eli Lilly And Company
    • 9.2.5 Gulf Pharmaceutical Industries PSC (Julphar)
    • 9.2.6 Novo Nordisk A/S
    • 9.2.7 Pfizer Inc
    • 9.2.8 Sanofi
    • 9.2.9 SEDICO Pharmaceutical Co
    • 9.2.10 Wockhardt Limited
    • 9.2.11 Ypsomed AG